采访加里·D·哈默，医学博士

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2019-12-01 DOI:10.2217/ije-2019-0017

G. Hammer

引用次数: 1

摘要

Hammer博士是Millendo Therapeutics（美国纳斯达克、MLND、密歇根州）的联合创始人和Vasaragen（美国密歇根州）这两家专注于罕见内分泌疾病的生物技术公司的创始人。哈默也是密歇根大学的一名员工。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An interview with Gary D Hammer, MD, PhD

Dr Hammer is the cofounder of Millendo Therapeutics (NASDAQ, MLND, MI, USA) and the founder of Vasaragen (MI, USA), two biotechnology companies focused on rare endocrine diseases. Hammer is also an employee of the University of Michigan.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.